沙库巴曲缬沙坦对慢性心力衰竭患者血心室重塑相关指标及心功能的影响  

Influence of sacubitril/valsartan on related indexes of ventricular remodeling and cardiac function in patients with chronic heart failure

作　　者：谢彩侠[1] 宣玲[1] 康品方[1] 黄宇理[1] 张恒[1] 唐碧[1] XIE Cai-xia;XUAN Ling;KANG Pin-fang;HUANG Yu-li;ZHANG Heng;TANG Bi(Department of Cardiology,the First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui 233004,China)

机构地区：[1]蚌埠医学院第一附属医院心血管科,安徽蚌埠233004

出　　处：《中华全科医学》2022年第12期2010-2014,共5页Chinese Journal of General Practice

基　　金：安徽省高校自然科学研究项目(KJ2018ZD023);蚌埠医学院第一批“512人才培育计划”(by51201214)。

摘　　要：目的通过测定慢性心力衰竭(CHF)患者应用沙库巴曲缬沙坦前后的血亲环素A(CyPA)、半乳糖凝集素3(Galectin-3)、基质金属蛋白酶2(MMP-2)、MMP-9、N端-脑钠肽(NT-proBNP)水平,探讨沙库巴曲缬沙坦对慢性心衰患者血心室重塑相关指标及心功能的影响。方法选取2018年12月—2022年6月于蚌埠医学院第一附属医院明确诊断为CHF并应用沙库巴曲缬沙坦的患者99例,分别收集其应用沙库巴曲缬沙坦前及应用后3个月的血标本,检测治疗前后血CyPA、Galectin-3、MMP-2、MMP-9、NT-proBNP水平。结果CHF患者应用沙库巴曲缬沙坦后血CyPA、Galectin-3、MMP-2、MMP-9、NT-proBNP水平明显低于应用前[CyPA:(7.75±3.18)ng/mL vs.(10.13±3.32)ng/mL;Galectin-3:(9.66±5.20)ng/mL vs.(16.74±3.18)ng/mL;MMP-2:(12.02±5.69)ng/mL vs.(18.40±8.41)ng/mL;MMP-9:(8.32±4.34)ng/mL vs.(11.45±4.51)ng/mL;NT-proBNP:(1319.24±404.11)ng/mL vs.(4187.48±1967.92)ng/mL,均P<0.01]。结论沙库巴曲缬沙坦能明显降低CHF患者血CyPA、Galectin-3、MMP-2、MMP-9、NT-proBNP水平,改善心功能,这可能对CHF的治疗效果评估有一定的作用。Objective By measuring the levels of blood cyclophilin A(CyPA),galectin-3,matrix metalloproteinase-2(MMP-2),MMP-9,N-terminal B type natriuretic peptide(NT-proBNP)in patients with chronic heart failure(CHF)before and after the application of sacubitril/valsartan,the effects of sacubitril/valsartan on related indexes of ventricular remodeling and cardiac function in patients with chronic heart failure were discussed.Methods We selected 99 cases with CHF treated with sacubitril/valsartan at the First Affiliated Hospital of Bengbu Medical College from December 2018 to June 2022.Blood samples were collected before and 3 months after treatment by sacubitril/valsartan,and the blood CyPA,galectin-3,MMP-2,MMP-9 and NT-proBNP levels before and after treatment by sacubitril/valsartan were compared.Results After treatment,the levels of blood CyPA,Galectin-3,MMP-2,MMP-9 and NT-proBNP in patients with CHF showed significant differences compared with those before treatment[CyPA:(7.75±3.18)ng/mL vs.(10.13±3.32)ng/mL;Galectin-3:(9.66±5.20)ng/mL vs.(16.74±3.18)ng/mL;MMP-2:(12.02±5.69)ng/mL vs.(18.40±8.41)ng/mL;MMP-9:(8.32±4.34)ng/mL vs.(11.45±4.51)ng/mL;NT-proBNP:(1319.24±404.11)ng/mL vs.(4187.48±1967.92)ng/mL,all P<0.01].Conclusion Sacubitril/valsartan can significantly reduce the levels of blood CyPA,Galectin-3,MMP-2,MMP-9 and NT-proBNP in patients with CHF and improve cardiac function,which may have certain effects on the evaluation of treatment with CHF.

关 键 词：沙库巴曲缬沙坦 血管紧张素受体-脑啡肽酶抑制剂 心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病] R972[医药卫生—内科学]